CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 22 enrolled
Drug / intervention
ziv-aflibercept +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00407485
NCT00407485Phase 2Completed
CompareCT.gov

A Phase II Study of VEGF Trap (NSC 724770) in Patients With Recurrent or Metastatic Transitional Carcinoma of the Urothelium

National Cancer Institute (NCI)·interventional·Posted Dec 5, 2006·Updated Oct 20, 2014

In Brief

A Phase 2 clinical trial evaluating ziv-aflibercept and pharmacological study for Adenocarcinoma of the Bladder and 12 related conditions. Completed, enrolled 22 participants across 1 site.

Detailed Summary

This phase II trial is studying the side effects and how well VEGF Trap works in treating patients with recurrent, locally advanced, or metastatic cancer of the urothelium. VEGF Trap may stop the growth of tumor cells by blocking blood flow to the tumor.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenocarcinoma of the Bladder, Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Squamous Cell Carcinoma of the Bladder, Stage III Bladder Cancer, Stage III Urethral Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder, Urethral Cancer Associated With Invasive Bladder Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 5, 2006
Enrollment StartNov 1, 2006
Primary CompletionApr 1, 2010
Study CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 19.6 years ago

Interventions

ziv-afliberceptbiological

Given IV

pharmacological studyother

Correlative studies